September 18, 2024
A Massachusetts biotech company won dismissal Wednesday from a proposed class action by investors who say their shares tanked in value after it allegedly came to light that executives had falsely touted an unproven prospective COVID-19 medicine.
April 18, 2023
Robbins Geller Rudman & Dowd LLP and Johnson Fistel LLP seek to jointly lead a proposed class action accusing executives of a biotech company of making empty boasts about the ability of its COVID-19 vaccine to fight the Omicron variant to inflate the stock price.
January 31, 2023
An investor in the biotech company formerly known as Adagio Therapeutics Inc. filed suit Monday in Boston federal court, claiming executives made empty boasts about its COVID-19 vaccine and caused the stock price to tank after the results showed the drug didn't work against the Omicron variant.